Feb. 4 at 5:00 PM
$RIGL Financial strength for R&D: Lilly reported a 43% increase in revenue (
$19.3 billion) and increased its R&D budget by 26% to
$3.8 billion to accelerate its pipeline. This gives Lilly the resources to aggressively pursue clinical development of ocadusertib (formerly R552) without budget constraints. Focus on inflammation: In addition to its success in obesity, Lilly emphasized growth in its immunology portfolio (such as Omvoh and Ebglyss). Ocadusertib fits perfectly with this strategic focus as a potential treatment for rheumatoid arthritis. Confirmation of milestones: Rigel anticipates approximately
$20 to
$25 million in contract revenue in its 2026 guidance. Lilly's strong performance reduces the risk of early-stage projects being discontinued to cut costs, increasing the likelihood of achieving the
$835 million milestone payments.
